Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Interaction of serotonin with Candida albicans selectively attenuates fungal virulence in vitro.

Mayr A, Hinterberger G, Dierich MP, Lass-Flörl C.

Int J Antimicrob Agents. 2005 Oct;26(4):335-7.

2.

Interaction of sertraline with Candida species selectively attenuates fungal virulence in vitro.

Lass-Flörl C, Ledochowski M, Fuchs D, Speth C, Kacani L, Dierich MP, Fuchs A, Würzner R.

FEMS Immunol Med Microbiol. 2003 Jan 21;35(1):11-5.

3.
4.

Phosphatidylinositol 3-kinase VPS34 of Candida albicans is involved in filamentous growth, secretion of aspartic proteases, and intracellular detoxification.

Kitanovic A, Nguyen M, Vogl G, Hartmann A, Günther J, Würzner R, Künkel W, Wölfl S, Eck R.

FEMS Yeast Res. 2005 Feb;5(4-5):431-9.

5.

In vitro study of secreted aspartyl proteinases Sap1 to Sap3 and Sap4 to Sap6 expression in Candida albicans pleomorphic forms.

Staniszewska M, Bondaryk M, Siennicka K, Kurek A, Orłowski J, Schaller M, Kurzatkowski W.

Pol J Microbiol. 2012;61(4):247-56.

6.

Antifungal properties of 5-hydroxytryptamine (serotonin) against Candida species in vitro.

Lass-Flörl C, Fuchs D, Ledochowski M, Speth C, Dierich MP, Würzner R.

J Med Microbiol. 2003 Feb;52(Pt 2):169-71.

PMID:
12543924
7.

Ocimum sanctum essential oil inhibits virulence attributes in Candida albicans.

Khan A, Ahmad A, Xess I, Khan LA, Manzoor N.

Phytomedicine. 2014 Mar 15;21(4):448-52. doi: 10.1016/j.phymed.2013.10.028. Epub 2013 Nov 17.

PMID:
24252340
8.

Effect of ritonavir and saquinavir on Candida albicans growth rate and in vitro activity of aspartyl proteinases.

Blanco MT, Hurtado C, Pérez-Giraldo C, Morán FJ, González-Velasco C, Gómez-García AC.

Med Mycol. 2003 Apr;41(2):167-70.

PMID:
12964850
9.

Candida albicans secreted aspartyl proteinases in virulence and pathogenesis.

Naglik JR, Challacombe SJ, Hube B.

Microbiol Mol Biol Rev. 2003 Sep;67(3):400-28, table of contents. Review.

10.
11.

Inhibition of hyphae formation and SIR2 expression in Candida albicans treated with fresh Allium sativum (garlic) extract.

Low CF, Chong PP, Yong PV, Lim CS, Ahmad Z, Othman F.

J Appl Microbiol. 2008 Dec;105(6):2169-77. doi: 10.1111/j.1365-2672.2008.03912.x.

12.

Inhibitory Effect of Sophorolipid on Candida albicans Biofilm Formation and Hyphal Growth.

Haque F, Alfatah M, Ganesan K, Bhattacharyya MS.

Sci Rep. 2016 Mar 31;6:23575. doi: 10.1038/srep23575.

13.

Phospholipase and proteinase activities of clinical isolates of Candida from immunocompromised patients.

Kumar CP, Kumar SS, Menon T.

Mycopathologia. 2006 Apr;161(4):213-8.

PMID:
16552483
14.

Profile of Candida albicans-secreted aspartic proteinase elicited during vaginal infection.

Taylor BN, Staib P, Binder A, Biesemeier A, Sehnal M, Röllinghoff M, Morschhäuser J, Schröppel K.

Infect Immun. 2005 Mar;73(3):1828-35.

15.

Trailing end-point phenotype antibiotic-sensitive strains of Candida albicans produce different amounts of aspartyl peptidases.

Braga-Silva LA, Mesquita DG, Ribeiro MD, Carvalho SM, Fracalanzza SE, Santos AL.

Braz J Med Biol Res. 2009 Aug;42(8):765-70.

16.

Resveratrol impaired the morphological transition of Candida albicans under various hyphae-inducing conditions.

Okamoto-Shibayama K, Sato Y, Azuma T.

J Microbiol Biotechnol. 2010 May;20(5):942-5.

17.

TOP2 gene is involved in the pathogenicity of Candida albicans.

Zheng H, Yu YS.

Mol Cell Biochem. 2012 May;364(1-2):45-52. doi: 10.1007/s11010-011-1203-9. Epub 2011 Dec 28.

PMID:
22203422
18.

Candida albicans secreted aspartyl proteinases.

Hube B.

Curr Top Med Mycol. 1996 Dec;7(1):55-69. Review.

PMID:
9504059
19.

Amphotericin B resistance leads to enhanced proteinase and phospholipase activity and reduced germ tube formation in Candida albicans.

Kumar R, Shukla PK.

Fungal Biol. 2010 Feb-Mar;114(2-3):189-97. doi: 10.1016/j.funbio.2009.12.003. Epub 2009 Dec 22.

PMID:
20943129
20.

Tetracycline-inducible expression of individual secreted aspartic proteases in Candida albicans allows isoenzyme-specific inhibitor screening.

Staib P, Lermann U, Blass-Warmuth J, Degel B, Würzner R, Monod M, Schirmeister T, Morschhäuser J.

Antimicrob Agents Chemother. 2008 Jan;52(1):146-56. Epub 2007 Oct 22.

Supplemental Content

Support Center